The FDA-approved pilot is structured to enable transparency and open testing. The final report to the FDA will publish aggregated results of the testing. Vantage will be providing independent oversight of test execution and aggregation of the results. The company will generate a report summarizing the results of the testing. Vantage has deep experience working with a variety of track and trace equipment and solution providers on Level 1 through 4 systems, giving the company a broad and unbiased perspective on the implementation and evaluation of the pilot testing. Vantage looks forward to contributing to the pilot and helping support industry to effectively comply with the FDA’s DSCSA requirements.”We are overwhelmed by the positive response from many VRS stakeholders to the FDA Pilot,” said Herb Wong, rfxcel’s executive sponsor for the FDA pilot. “Vantage’s independent review of the results will give added confidence regarding the testing. Their commitment to this effort highlights Vantage’s commitment to the industry. rfxcel looks forward to the insight and leadership they will provide to the FDA pilot.
Read more on Contract Pharma
